{"id":61508,"date":"2025-10-27T15:05:18","date_gmt":"2025-10-27T14:05:18","guid":{"rendered":"https:\/\/www.inovallee.com\/?p=61508"},"modified":"2025-10-27T15:05:19","modified_gmt":"2025-10-27T14:05:19","slug":"biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager","status":"publish","type":"post","link":"http:\/\/www.inovallee.com\/en\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\/","title":{"rendered":"Biotech\u00a0: Dillico l\u00e8ve 7,5 M\u20ac pour commercialiser sa technologie unique de production de vaccins et th\u00e9rapies \u00e0 ARN messager"},"content":{"rendered":"<p><strong>La biotech Dillico, install\u00e9e \u00e0 inovall\u00e9e, franchit une \u00e9tape d\u00e9cisive dans son d\u00e9veloppement avec la cl\u00f4ture d\u2019un tour de financement de 7,5 millions d\u2019euros. Objectif : lancer la commercialisation de sa solution innovante de production de vaccins et th\u00e9rapies \u00e0 ARN messager, une technologie de rupture qui pourrait transformer l\u2019acc\u00e8s \u00e0 la m\u00e9decine personnalis\u00e9e.<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Une technologie de production ultra-flexible pour l\u2019ARNm<\/strong><\/h3>\n\n\n\n<p>Cofond\u00e9e en mai 2022 sur inovall\u00e9e par des experts de l\u2019industrie pharmaceutique, <a href=\"https:\/\/dillico.com\/\">Dillico<\/a> d\u00e9veloppe All-ScaleFlow\u2122, une plateforme int\u00e9gr\u00e9e, digitalis\u00e9e et adapt\u00e9e \u00e0 toutes les \u00e9chelles de production. Cette solution permet de fabriquer rapidement et efficacement des m\u00e9dicaments \u00e0 base d\u2019ARN messager, notamment pour des indications complexes comme les cancers sans traitement curatif.<\/p>\n\n\n\n<p>La technologie de Dillico vise \u00e0 d\u00e9mocratiser l\u2019acc\u00e8s \u00e0 l\u2019immuno-oncologie personnalis\u00e9e, en rendant la production plus agile, plus rentable et plus adapt\u00e9e aux besoins sp\u00e9cifiques des patients.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Un tour de table strat\u00e9gique pour acc\u00e9l\u00e9rer la mise sur le march\u00e9<\/strong><\/h3>\n\n\n\n<p>La lev\u00e9e de fonds a \u00e9t\u00e9 r\u00e9alis\u00e9e aupr\u00e8s d\u2019un consortium d\u2019investisseurs engag\u00e9s dans l\u2019innovation de rupture : Angelor (via son fonds For Good), le Fonds R\u00e9gional Avenir Industrie Auvergne-Rh\u00f4ne-Alpes (conseill\u00e9 par UI Investissement), le fonds French Tech Seed g\u00e9r\u00e9 par Bpifrance dans le cadre de France 2030, ainsi que les fonds GP Compas et Deepbright One. Des investisseurs priv\u00e9s et Family Offices, dont l\u2019investisseur historique Deeperly, compl\u00e8tent ce tour de table.<\/p>\n\n\n\n<p>Ce financement en capital est renforc\u00e9 par un soutien non dilutif de 2,4 M\u20ac via France 2030 et un nouveau financement bancaire, permettant \u00e0 Dillico de s\u00e9curiser les ressources n\u00e9cessaires pour industrialiser sa solution.<\/p>\n\n\n\n<p>\u00ab Ce tour de financement place Dillico dans une trajectoire tr\u00e8s directe vers le march\u00e9 \u00bb, souligne Christophe Bonneville, Pr\u00e9sident et CEO de Dillico. \u00ab Notre pilote industriel a d\u00e9j\u00e0 \u00e9t\u00e9 test\u00e9 avec succ\u00e8s par des acteurs majeurs du secteur. \u00bb<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Un soutien fort des partenaires publics et priv\u00e9s<\/strong><\/h3>\n\n\n\n<p>Les investisseurs saluent la qualit\u00e9 de l\u2019\u00e9quipe fondatrice et le potentiel de transformation de la technologie d\u00e9velopp\u00e9e par Dillico.<\/p>\n\n\n\n<p>\u00ab Nous avons \u00e9t\u00e9 impressionn\u00e9s par la compl\u00e9mentarit\u00e9 de l\u2019\u00e9quipe et les b\u00e9n\u00e9fices de la plateforme en termes de qualit\u00e9, de rendement et de modularit\u00e9 \u00bb, explique Marie Chambodut, Directrice G\u00e9n\u00e9rale d\u2019Angelor.<\/p>\n\n\n\n<p>\u00ab Le proc\u00e9d\u00e9 de fabrication mis en place par Dillico repr\u00e9sente une r\u00e9elle rupture technologique \u00bb, ajoute Eva Clerc, Directrice d\u2019investissement senior chez Bpifrance. \u00ab Il permettra de d\u00e9mocratiser l\u2019acc\u00e8s aux th\u00e9rapies \u00e0 base d\u2019ARN messager. \u00bb<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Une biotech d\u2019avenir au c\u0153ur d\u2019inovall\u00e9e<\/strong><\/h3>\n\n\n\n<p>Avec cette lev\u00e9e de fonds, Dillico confirme son ambition : devenir un acteur cl\u00e9 de la production pharmaceutique nouvelle g\u00e9n\u00e9ration.<\/p>\n\n\n\n<p>Une ambition port\u00e9e depuis le c\u0153ur d\u2019inovall\u00e9e, o\u00f9 l\u2019innovation technologique et la sant\u00e9 de demain se rencontrent plus que jamais&nbsp;!<\/p>\n\n\n\n<p>Source&nbsp;: <a href=\"https:\/\/presse.bpifrance.fr\/dillico-annonce-la-cloture-dun-tour-de-financement-de-75-millions-pour-lancer-la-commercialisation-de-sa-solution-innovante-de-production-de-vaccins-et-therapies-a-arn-messager\">https:\/\/presse.bpifrance.fr\/dillico-annonce-la-cloture-dun-tour-de-financement-de-75-millions-pour-lancer-la-commercialisation-de-sa-solution-innovante-de-production-de-vaccins-et-therapies-a-arn-messager<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>La biotech Dillico, install\u00e9e \u00e0 inovall\u00e9e, franchit une \u00e9tape d\u00e9cisive dans son d\u00e9veloppement avec la cl\u00f4ture d\u2019un tour de financement de 7,5 millions d\u2019euros. Objectif : lancer la commercialisation de sa solution innovante de production de vaccins et th\u00e9rapies \u00e0 ARN messager, une technologie de rupture qui pourrait transformer l\u2019acc\u00e8s \u00e0 la m\u00e9decine personnalis\u00e9e. Une [&hellip;]<\/p>\n","protected":false},"author":18,"featured_media":61509,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[28],"tags":[1948],"class_list":["post-61508","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actus-entreprises","tag-dillico"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Biotech\u00a0: Dillico l\u00e8ve 7,5 M\u20ac pour commercialiser sa technologie unique de production de vaccins et th\u00e9rapies \u00e0 ARN messager - inovall\u00e9e<\/title>\n<meta name=\"description\" content=\"La biotech Dillico, install\u00e9e \u00e0 inovall\u00e9e franchit une \u00e9tape d\u00e9cisive dans son d\u00e9veloppement pour lancer la commercialisation de sa solution innovante de production de vaccins et th\u00e9rapies \u00e0 ARN messager.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.inovallee.com\/en\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biotech\u00a0: Dillico l\u00e8ve 7,5 M\u20ac pour commercialiser sa technologie unique de production de vaccins et th\u00e9rapies \u00e0 ARN messager - inovall\u00e9e\" \/>\n<meta property=\"og:description\" content=\"La biotech Dillico, install\u00e9e \u00e0 inovall\u00e9e franchit une \u00e9tape d\u00e9cisive dans son d\u00e9veloppement pour lancer la commercialisation de sa solution innovante de production de vaccins et th\u00e9rapies \u00e0 ARN messager.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.inovallee.com\/en\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\/\" \/>\n<meta property=\"og:site_name\" content=\"inovall\u00e9e\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/technopoleinovallee\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-27T14:05:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-27T14:05:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.inovallee.com\/wp-content\/uploads\/2025\/10\/image-16.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"756\" \/>\n\t<meta property=\"og:image:height\" content=\"425\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Margaux De la Fuente\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@inovallee\" \/>\n<meta name=\"twitter:site\" content=\"@inovallee\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Margaux De la Fuente\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\\\/\"},\"author\":{\"name\":\"Margaux De la Fuente\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#\\\/schema\\\/person\\\/92dc7fd313568f5cc54aba72aba732fe\"},\"headline\":\"Biotech\u00a0: Dillico l\u00e8ve 7,5 M\u20ac pour commercialiser sa technologie unique de production de vaccins et th\u00e9rapies \u00e0 ARN messager\",\"datePublished\":\"2025-10-27T14:05:18+00:00\",\"dateModified\":\"2025-10-27T14:05:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\\\/\"},\"wordCount\":527,\"publisher\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.inovallee.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/image-16.jpeg\",\"keywords\":[\"Dillico\"],\"articleSection\":[\"Sucess stories des entreprises d'inovall\u00e9e\"],\"inLanguage\":\"en-GB\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\\\/\",\"url\":\"https:\\\/\\\/www.inovallee.com\\\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\\\/\",\"name\":\"Biotech\u00a0: Dillico l\u00e8ve 7,5 M\u20ac pour commercialiser sa technologie unique de production de vaccins et th\u00e9rapies \u00e0 ARN messager - inovall\u00e9e\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.inovallee.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/image-16.jpeg\",\"datePublished\":\"2025-10-27T14:05:18+00:00\",\"dateModified\":\"2025-10-27T14:05:19+00:00\",\"description\":\"La biotech Dillico, install\u00e9e \u00e0 inovall\u00e9e franchit une \u00e9tape d\u00e9cisive dans son d\u00e9veloppement pour lancer la commercialisation de sa solution innovante de production de vaccins et th\u00e9rapies \u00e0 ARN messager.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.inovallee.com\\\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.inovallee.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/image-16.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.inovallee.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/image-16.jpeg\",\"width\":756,\"height\":425},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.inovallee.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biotech\u00a0: Dillico l\u00e8ve 7,5 M\u20ac pour commercialiser sa technologie unique de production de vaccins et th\u00e9rapies \u00e0 ARN messager\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#website\",\"url\":\"https:\\\/\\\/www.inovallee.com\\\/\",\"name\":\"inovall\u00e9e technopole, Home to software & smart technologies\",\"description\":\"Home to software &amp; smart technologies\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.inovallee.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#organization\",\"name\":\"inovall\u00e9e\",\"url\":\"https:\\\/\\\/www.inovallee.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.inovallee.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/inovallee_2022_GrenobleAlpes.png\",\"contentUrl\":\"https:\\\/\\\/www.inovallee.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/inovallee_2022_GrenobleAlpes.png\",\"width\":945,\"height\":369,\"caption\":\"inovall\u00e9e\"},\"image\":{\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/technopoleinovallee\\\/\",\"https:\\\/\\\/x.com\\\/inovallee\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/inovall-e\\\/\",\"https:\\\/\\\/www.youtube.com\\\/user\\\/inovallee?reload=9\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.inovallee.com\\\/#\\\/schema\\\/person\\\/92dc7fd313568f5cc54aba72aba732fe\",\"name\":\"Margaux De la Fuente\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biotech\u00a0: Dillico l\u00e8ve 7,5 M\u20ac pour commercialiser sa technologie unique de production de vaccins et th\u00e9rapies \u00e0 ARN messager - inovall\u00e9e","description":"La biotech Dillico, install\u00e9e \u00e0 inovall\u00e9e franchit une \u00e9tape d\u00e9cisive dans son d\u00e9veloppement pour lancer la commercialisation de sa solution innovante de production de vaccins et th\u00e9rapies \u00e0 ARN messager.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.inovallee.com\/en\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\/","og_locale":"en_GB","og_type":"article","og_title":"Biotech\u00a0: Dillico l\u00e8ve 7,5 M\u20ac pour commercialiser sa technologie unique de production de vaccins et th\u00e9rapies \u00e0 ARN messager - inovall\u00e9e","og_description":"La biotech Dillico, install\u00e9e \u00e0 inovall\u00e9e franchit une \u00e9tape d\u00e9cisive dans son d\u00e9veloppement pour lancer la commercialisation de sa solution innovante de production de vaccins et th\u00e9rapies \u00e0 ARN messager.","og_url":"https:\/\/www.inovallee.com\/en\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\/","og_site_name":"inovall\u00e9e","article_publisher":"https:\/\/www.facebook.com\/technopoleinovallee\/","article_published_time":"2025-10-27T14:05:18+00:00","article_modified_time":"2025-10-27T14:05:19+00:00","og_image":[{"width":756,"height":425,"url":"https:\/\/www.inovallee.com\/wp-content\/uploads\/2025\/10\/image-16.jpeg","type":"image\/jpeg"}],"author":"Margaux De la Fuente","twitter_card":"summary_large_image","twitter_creator":"@inovallee","twitter_site":"@inovallee","twitter_misc":{"Written by":"Margaux De la Fuente","Estimated reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.inovallee.com\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\/#article","isPartOf":{"@id":"https:\/\/www.inovallee.com\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\/"},"author":{"name":"Margaux De la Fuente","@id":"https:\/\/www.inovallee.com\/#\/schema\/person\/92dc7fd313568f5cc54aba72aba732fe"},"headline":"Biotech\u00a0: Dillico l\u00e8ve 7,5 M\u20ac pour commercialiser sa technologie unique de production de vaccins et th\u00e9rapies \u00e0 ARN messager","datePublished":"2025-10-27T14:05:18+00:00","dateModified":"2025-10-27T14:05:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.inovallee.com\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\/"},"wordCount":527,"publisher":{"@id":"https:\/\/www.inovallee.com\/#organization"},"image":{"@id":"https:\/\/www.inovallee.com\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\/#primaryimage"},"thumbnailUrl":"https:\/\/www.inovallee.com\/wp-content\/uploads\/2025\/10\/image-16.jpeg","keywords":["Dillico"],"articleSection":["Sucess stories des entreprises d'inovall\u00e9e"],"inLanguage":"en-GB"},{"@type":"WebPage","@id":"https:\/\/www.inovallee.com\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\/","url":"https:\/\/www.inovallee.com\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\/","name":"Biotech\u00a0: Dillico l\u00e8ve 7,5 M\u20ac pour commercialiser sa technologie unique de production de vaccins et th\u00e9rapies \u00e0 ARN messager - inovall\u00e9e","isPartOf":{"@id":"https:\/\/www.inovallee.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.inovallee.com\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\/#primaryimage"},"image":{"@id":"https:\/\/www.inovallee.com\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\/#primaryimage"},"thumbnailUrl":"https:\/\/www.inovallee.com\/wp-content\/uploads\/2025\/10\/image-16.jpeg","datePublished":"2025-10-27T14:05:18+00:00","dateModified":"2025-10-27T14:05:19+00:00","description":"La biotech Dillico, install\u00e9e \u00e0 inovall\u00e9e franchit une \u00e9tape d\u00e9cisive dans son d\u00e9veloppement pour lancer la commercialisation de sa solution innovante de production de vaccins et th\u00e9rapies \u00e0 ARN messager.","breadcrumb":{"@id":"https:\/\/www.inovallee.com\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.inovallee.com\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.inovallee.com\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\/#primaryimage","url":"https:\/\/www.inovallee.com\/wp-content\/uploads\/2025\/10\/image-16.jpeg","contentUrl":"https:\/\/www.inovallee.com\/wp-content\/uploads\/2025\/10\/image-16.jpeg","width":756,"height":425},{"@type":"BreadcrumbList","@id":"https:\/\/www.inovallee.com\/biotech-dillico-leve-75-me-pour-commercialiser-sa-technologie-unique-de-production-de-vaccins-et-therapies-a-arn-messager\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.inovallee.com\/"},{"@type":"ListItem","position":2,"name":"Biotech\u00a0: Dillico l\u00e8ve 7,5 M\u20ac pour commercialiser sa technologie unique de production de vaccins et th\u00e9rapies \u00e0 ARN messager"}]},{"@type":"WebSite","@id":"https:\/\/www.inovallee.com\/#website","url":"https:\/\/www.inovallee.com\/","name":"inovall\u00e9e technopole, Home to software & smart technologies","description":"Home to software &amp; smart technologies","publisher":{"@id":"https:\/\/www.inovallee.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.inovallee.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/www.inovallee.com\/#organization","name":"inovall\u00e9e","url":"https:\/\/www.inovallee.com\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.inovallee.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.inovallee.com\/wp-content\/uploads\/2023\/08\/inovallee_2022_GrenobleAlpes.png","contentUrl":"https:\/\/www.inovallee.com\/wp-content\/uploads\/2023\/08\/inovallee_2022_GrenobleAlpes.png","width":945,"height":369,"caption":"inovall\u00e9e"},"image":{"@id":"https:\/\/www.inovallee.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/technopoleinovallee\/","https:\/\/x.com\/inovallee","https:\/\/www.linkedin.com\/company\/inovall-e\/","https:\/\/www.youtube.com\/user\/inovallee?reload=9"]},{"@type":"Person","@id":"https:\/\/www.inovallee.com\/#\/schema\/person\/92dc7fd313568f5cc54aba72aba732fe","name":"Margaux De la Fuente"}]}},"_links":{"self":[{"href":"http:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/posts\/61508","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/users\/18"}],"replies":[{"embeddable":true,"href":"http:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/comments?post=61508"}],"version-history":[{"count":2,"href":"http:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/posts\/61508\/revisions"}],"predecessor-version":[{"id":61512,"href":"http:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/posts\/61508\/revisions\/61512"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/media\/61509"}],"wp:attachment":[{"href":"http:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/media?parent=61508"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/categories?post=61508"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.inovallee.com\/en\/wp-json\/wp\/v2\/tags?post=61508"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}